Bevacizumab dose-rounding policy leads to significant cost savings
Rounding the dose of bevacizumab to the nearest vial size leads to substantial cost savings and does not significantly influence the incidence of adverse events, a recent study has found.
Between 1 August 2014 and 31 May 2016, 55 patients received at least one dose of bevacizumab, with a total of 470 doses administered to patients. Dose rounding of bevacizumab to the nearest 100 mg during the study time period led to an estimated cost savings of $164,617.92.
The rates of adverse events were comparable between patients who received either a dose that was rounded up or rounded down to the nearest 100 mg.
A retrospective chart review of all patients receiving at least one rounded dose of bevacizumab over a period of 22 months was conducted to assess potential cost savings incurred from such a policy and to determine difference in rates of adverse events among patients.
Bevacizumab doses were calculated based on actual body weight, and were then rounded to the nearest 400 or 100 mg vial size. The authors calculated the predicted effect on cost in US dollars for both the prerounded dose and the rounded dose.
Adverse events (eg, hypertension, proteinuria and vascular events) were compared between patients who received a dose that was rounded up and those with a dose rounded down.
Another study found that a practical dose down-rounding procedure was associated with a significant cost reduction in metastatic cancer setting, where the cure is not the goal. Drug waste could be prevented by convenient vial sized or could even be eliminated by lyophilized forms like in trastuzumab. [J Oncol Pharm Pract 2017;1:1078155217692400]
“Our data reflect the monoclonal antibody use and potential cost savings with the proposed dose down-rounding approach in a community-based cancer programme,” researchers said.